Bo Zhang

Bo Zhang

Auto-generated profile, based on publicly available information

Bo Zhang

Department of Biosciences and Nutrition – Neo, AstraZeneca, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cell
Verified
Journal Article
Closed access
YHYong Hou
Yong Hou
LSLuting Song
Luting Song
PZPing Zhu
Ping Zhu
BZBo Zhang
Bo Zhang
YTYe Tao
Ye Tao
JWJun Wang
Jun Wang

1 November 2013 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
MPMohammad Pirmoradian
Mohammad Pirmoradian
HBHarshavardhan Budamgunta
Harshavardhan Budamgunta
KCKonstantin Chingin
Konstantin Chingin
BZBo Zhang
Bo Zhang
JAJuan Astorga-Wells
Juan Astorga-Wells
JZJanet Zubarev
Janet Zubarev
Multiparameter optimization of an LC-MS/MS shotgun proteomics experiment was performed without any hardware or software modification of the commercial instrument. Under the optimized experimental conditions, with a 50-cm-long separation column and a 4-h LC-MS run (including a 3-h optimized gradient), 4,825 protein groups and 37,550 peptides were identified in a single run and 5,354 protein groups and 56,390 peptides in a triplicate analysis of the A375 human cell line, for approximately 50% coverage of the expressed proteome. The major steps enabling such performance included optimization of the cell lysis and protein extraction, digestion of even insoluble cell debris, tailoring the LC gradient profile, and choosing the optimal dynamic exclusion window in data-dependent MS/MS, as well as the optimal m/z scan window.

14 June 2018 in Blood
Verified
Journal Article
Closed access
PDF file
WRWeicheng Ren
Weicheng Ren
XYXiaofei Ye
Xiaofei Ye
HSHong Su
Hong Su
WLWei Li
Wei Li
DLDongbing Liu
Dongbing Liu
QPQiang Pan-Hammarström
Qiang Pan-Hammarström
Hepatitis B virus (HBV) infection is endemic in some parts of Asia, Africa, and South America and remains to be a significant public health problem in these areas. It is known as a leading risk factor for the development of hepatocellular carcinoma, but epidemiological studies have also shown that the infection may increase the incidence of several types of B-cell lymphoma. Here, by characterizing altogether 275 Chinese diffuse large B-cell lymphoma (DLBCL) patients, we showed that patients with concomitant HBV infection (surface antigen positive [HBsAg+]) are characterized by a younger age, a more advanced disease stage at diagnosis, and reduced overall survival. Furthermore, by whole-genome/exome sequencing of 96 tumors and the respective peripheral blood samples and targeted sequencing of 179 tumors from these patients, we observed an enhanced rate of mutagenesis and a distinct set of mutation targets in HBsAg+ DLBCL genomes, which could be partially explained by the activities of APOBEC and activation-induced cytidine deaminase. By transcriptome analysis, we further showed that the HBV-associated gene expression signature is contributed by the enrichment of genes regulated by BCL6, FOXO1, and ZFP36L1. Finally, by analysis of immunoglobulin heavy chain gene sequences, we showed that an antigen-independent mechanism, rather than a chronic antigenic simulation model, is favored in HBV-related lymphomagenesis. Taken together, we present the first comprehensive genomic and transcriptomic study that suggests a link between HBV infection and B-cell malignancy. The genetic alterations identified in this study may also provide opportunities for development of novel therapeutic strategies. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points DLBCL patients with concomitant HBV infection are characterized by distinct clinical features. Genomic and transcriptomic analyses identified distinct mutation targets and tumorigenic pathways in HBV-associated DLBCLs. Visual Abstract

14 August 2012 in GigaScience
Verified
Journal Article
Open access
PDF file
YLYingrui Li
Yingrui Li
XXXun Xu
Xun Xu
LSLuting Song
Luting Song
YHYong Hou
Yong Hou
ZLZesong Li
Zesong Li
JWJun Wang
Jun Wang
Background. Cancers arise through an evolutionary process in which cell populations are subjected to selection; however, to date, the process of bladder

1 May 2017 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
BZBo Zhang
Bo Zhang
MPMohammad Pirmoradian
Mohammad Pirmoradian
JZJanet Zubarev
Janet Zubarev
LKLukas Käll
Lukas Käll
Most implementations of mass spectrometry-based proteomics involve enzymatic digestion of proteins, expanding the analysis to multiple proteolytic peptides for each protein. Currently, there is no consensus of how to summarize peptides' abundances to protein concentrations, and such efforts are complicated by the fact that error control normally is applied to the identification process, and do not directly control errors linking peptide abundance measures to protein concentration. Peptides resulting from suboptimal digestion or being partially modified are not representative of the protein concentration. Without a mechanism to remove such unrepresentative peptides, their abundance adversely impacts the estimation of their protein's concentration. Here, we present a relative quantification approach, Diffacto, that applies factor analysis to extract the covariation of peptides' abundances. The method enables a weighted geometrical average summarization and automatic elimination of incoherent peptides. We demonstrate, based on a set of controlled label-free experiments using standard mixtures of proteins, that the covariation structure extracted by the factor analysis accurately reflects protein concentrations. In the 1% peptide-spectrum match-level FDR data set, as many as 11% of the peptides have abundance differences incoherent with the other peptides attributed to the same protein. If not controlled, such contradicting peptide abundance have a severe impact on protein quantifications. When adding the quantities of each protein's three most abundant peptides, we note as many as 14% of the proteins being estimated as having a negative correlation with their actual concentration differences between samples. Diffacto reduced the amount of such obviously incorrectly quantified proteins to 1.6%. Furthermore, by analyzing clinical data sets from two breast cancer studies, our method revealed the persistent proteomic signatures linked to three subtypes of breast cancer. We conclude that Diffacto can facilitate the interpretation and enhance the utility of most types of proteomics data.

16 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Amirata Saei DibavarAmirata Saei Dibavar
Amirata Saei Dibavar
CBChristian Michel Beusch
Christian Michel Beusch
ACAlexey Chernobrovkin
Alexey Chernobrovkin
PSPierre Sabatier
Pierre Sabatier
BZBo Zhang
Bo Zhang
JZJanet Zubarev
Janet Zubarev
Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com. For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery.